Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis

Pietinalho, Anne; Tukiainen, P; Haahtela, Tari; Persson, Tore; Selroos, Olof

doi:10.1378/chest.116.2.424

Cited by 101 publications

(54 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 3 summarises clinical trials using these agents, including the clinical outcome. For patients with no symptoms and no evidence of parenchymal lung disease, there was no difference in treatment with corticosteroids versus placebo [16]. For patients with parenchymal lung disease on chest radiography but no symptoms, treatment for 18 months with glucocorticoids was better than placebo 5 years after initiation of therapy [14,87].…”

Section: Individual Drugs For Pulmonary Sarcoidosismentioning

confidence: 98%

“…There was a significant improvement, compared placebo treated patients, in some corticosteroid studies [16,42] while not in others [14]. The advantage of this measure is that it is more sensitive to interstitial lung disease [5].…”

Section: Pulmonary Functionmentioning

confidence: 99%

“…However, in placebo controlled trials, it is not clear that the response is greater than that seen with placebo [3]. As demonstrated in table 2, the treatment schedule and duration of follow-up leads to differences in response to corticosteroids [14,16,17]. In some studies, an initial improvement was not maintained [32].…”

Section: Pulmonary Functionmentioning

confidence: 99%

“…Budesonide, at doses of 800 mg twice a day, has been shown to be effective at maintaining the improvement achieved with oral glucocorticoids [16]. However, not all studies found budesonide was effective in treating pulmonary disease [83].…”

Section: Individual Drugs For Pulmonary Sarcoidosismentioning

confidence: 99%

See 3 more Smart Citations

Established and experimental medical therapy of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As new treatments have been introduced, the best way to assess and compare treatments remains unknown. The goal of this review is to discuss the standard treatments for pulmonary sarcoidosis, including glucocorticoids, and cytotoxic agents, such as methotrexate, azathioprine and leflunomide, and compare them to the newer biological agents, such as infliximab and adalimumab. We also discuss some novel treatments which are currently being evaluated. To compare these different regimens, we look at the measures used to assess response. These include pulmonary function, chest imaging, steroid sparing potential and, more recently, improvements in quality of life measures. While there is, as yet, no standard assessment for response, there is a growing consensus that response to treatment may include improvement of one or more of the following: forced vital capacity, chest imaging and steroid sparing. Several drugs used for pulmonary sarcoidosis have demonstrated improvement in one or more of these measures.

show abstract

Section: Individual Drugs For Pulmonary Sarcoidosismentioning

confidence: 98%

Section: Pulmonary Functionmentioning

confidence: 99%

Section: Pulmonary Functionmentioning

confidence: 99%

Section: Individual Drugs For Pulmonary Sarcoidosismentioning

confidence: 99%

See 2 more Smart Citations

Established and experimental medical therapy of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…They found no beneficial effect from the use of inhaled budesonide. Pietinalho et al (Pietinalho et al, 1999) compared a group of patients initially treated with 10-20mg prednisolone during 3 months, followed by inhaled budesonide at 1.6mg/day during 15 months, with a control group that received a placebo. After 3 months of treatment, a radiological improvement was observed in the treatment group compared to the control group.…”

Section: Inhaled Corticosteroidsmentioning

confidence: 99%